Oral NXC-736 tested for alopecia areata in adults
Tests the pill NXC-736 against placebo in adults with alopecia areata.
Key facts
- Who runs it
- NEXTGEN Bioscience
- Where
- South Korea2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 73 people, planned
- Started
- 1 Sept 2024
- Expected to end
- 31 Jan 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- NXC736
- Placebo
- Record updated
- 13 April 2026
Who can take part
The trial is looking for adults with moderate or severe alopecia areata, a condition where the immune system causes patchy hair loss. It tests NXC736 taken by mouth against a placebo.
- Age
- 19 to 65 years
- Sex
- Men and women
- Disease stage
- Moderate or severe alopecia areata, with a SALT hair-loss score of 25% ≤ SALT < 95%. The current episode of hair loss has lasted ≥6 months but <8 years. There has been no clear hair regrowth in the last 6 months.
- Earlier treatment
- People who have used a Janus kinase (JAK) inhibitor before, by mouth or on the skin, cannot join. This includes taking part in JAK inhibitor studies.
- Main reasons for not taking part
- Other types of hair loss, such as scarring alopecia, traction alopecia, androgenic alopecia or telogen effluvium
- Active scalp inflammation, scalp infection or scalp psoriasis
- Any other scalp condition that could disturb the hair-loss score
- Past use of a JAK inhibitor
- Not willing to keep the same hair style and color during the study
Show the full registry criteria (8)Hide the full registry criteria
Who can take part
- Men or women between ≥19 and ≤65 years of age at the time of informed consent
- Moderate and severe alopecia areata as assessed by a SALT score of 25% ≤ SALT < 95% at Screening and Day 1/Baseline
- Current episode of hair loss for ≥6 months but <8 years
- Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator
- Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the study
Who cannot take part
- Previous use of Janus kinase (JAK) inhibitor (oral or topical), including participation in clinical studies of JAK inhibitors
- Active scalp inflammation, scalp infection, scalp psoriasis, or any other scalp condition that may interfere with the SALT assessment
- Participants with the following medical history confirmed during screening:; ohter Types of alopecia other than alopecia areata (such as cicatricial/scarring alopecia [including central centrifugal cicatricial alopecia], traction alopecia, androgenic alopecia, telogen effluvium, etc.)
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Alopecia areata
This trial is currently available in South Korea.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).
The 2 groups in the trial
- NXC736Treatment being tested
- PlaceboPlacebo, for comparison
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients With Moderate and Severe Alopecia Areata
- Plain-language title
- Oral NXC-736 tested for alopecia areata in adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT06104839, who can take part
- Record updated
- 13 April 2026